Afimmune

Afimmune is an Irish clinical-stage biotech developing novel small molecule drugs for rare and cardiometabolic diseases. Its lead program, Epeleuton, is a next-generation synthetic omega-3 fatty acid in clinical trials for Sickle Cell Disease (SCD), targeting both red blood cell health and vascular inflammation. Founded in 2015 by industry veterans with deep experience in clinical research, the company is privately held and appears to be pre-revenue, advancing its pipeline through clinical development. Afimmune's strategy focuses on addressing significant unmet needs in SCD, a serious inherited disorder with limited treatment options and high morbidity.

Development of novel synthetic bioactive lipids, specifically next-generation omega-3 fatty acid small molecule derivatives, designed for enhanced therapeutic effects in targeting inflammation and cellular health.

The Sickle Cell Disease treatment landscape is rapidly evolving, moving beyond supportive care with the approval of disease-modifying drugs like crizanlizumab and voxelotor, and the recent advent of curative but extremely expensive gene therapies (e.g., lovotibeglogene autotemcel). Afimmune's Epeleuton, as a potential oral, chronic therapy with a novel mechanism, would compete in a space defined by high innovation and significant unmet need, requiring clear differentiation on efficacy, safety, and convenience.